Notch signal protects non-parenchymal cells from ischemia/reperfusion injury in vitro by repressing ROS
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 5
Abstract
Background. We have previously reported that Notch signaling pathway protects hepatocytes from ischemia/ reperfusion (I/R) injury by repressing reactive oxygen species (ROS) production. However, apart from hepatocytes, non-parenchymal cells including vascular endothelia cells, Kupffer cells and hepatic stellate cells are also reported to be involved in hepatic I/R injury.Aim. To clarify the role of Notch signaling in non-parenchymal cells subjected to I/R injury.Materials and methods. Human Umbilical Vein Endothelial Cells (HUVECs), mouse macrophage line RAW264.7 and rat hepatic stellate cell line HSC-T6 were cultured and subjected to I/R injury, respectively. Activation of Notch signaling was assessed by NICD western blot. Then, pharmacological inhibitor (-secretase inhibitor GSI) was used to block Notch signaling of related cell lines in vitro. Intracellular ROS was detected and analyzed by FACS and apoptosis was examined by TUNEL staining and Annexin V staining. Results. Notch signaling responded to I/R injury and I/R injury induced activation of Notch signaling in nonparenchymal cells. Notch signal deficiency led to overproduction of ROS and aggravated cell death of non-parenchymal cells subjected to I/R injury. Conclusion. Notch signal protectes non-parenchymal cells from I/R injury by repressing ROS.
Authors and Affiliations
Heng-Chao Yu, Lu Bai, Shu-Qiang Yue, De-Sheng Wang, Lin Wang, Hua Han, Ke-Feng Dou
Keywords
Related Articles
- EP ID EP78324
- DOI -
- Views 122
- Downloads 0
A modified heterotopic auxiliary living donor liver transplantation: report of a case
Liver transplantation is regarded as an effective treatment for Wilson’s disease (WD), and recently has been shown to improve not only hepatic but also neurologic manifestations. Conventional auxiliary liver transplantat...
Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome
Background/Aims: Patients with primary Sjögren’s syndrome may present liver involvement. Our goals were to establish the prevalence of abnormal hepatic biochemistries and clinical liver disease in patients with primary S...
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy
[b]Introduction[/b]. Complete suppression of viral replication is crucial in chronic HCV treatment in order to prevent relapse and resistance development. We wanted to find out which factors influence the period from bei...
Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C.
Background. Chronic hepatitis C(CHC) staging is important for therapeutic decision-making. Identification of noninvasive markers can provide alternatives to liver biopsy. Aim. To assess the value of APRI and FIB4 for CH...
Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
Background and Aims. The risk of recurrent hepatitis B virus (HBV) infection and prognosis of liver transplantation in patients with HBV has dramatically changed with the use of prophylaxis including hepatitis B immune g...